IN THE traditional approach to managing stroke, questions that need to be asked and answered include the following: Who is at risk for stroke? What can we do about both preventing and treating stroke? Where is the brain injured? Where in the vascular system is the problem? Why, pathophysiologically, has this stroke occurred? and How (and when) do we implement therapies to minimize neurological disability? While hyperacute therapy with intravenous recombinant tissue-type plasminogen activator (rt-PA) is the most significant therapy to date that improves neurological outcome, it remains a potentially dangerous intervention.
Levine RL. One-Stop ShoppingStroke Questions Further Answered With Magnetic Resonance Imaging. Arch Neurol. 2001;58(4):555-556. doi:10.1001/archneur.58.4.555